CCR7 and glioblastoma: CCR7 inhibition using neutralizing antibodies alone did not reduce Gbm95 or GL261 cell viability, however, CCR7 inhibition increased GBM cell sensitivity to chemotherapy with TMZ, which is the current gold standard therapy for GBM (Fig. 5a, b, Supplementary Fig. 5a, b).